Skip to content
Disclosery

SR One Capital Management, LP

Follow

13F filer, CIK 1910264, Redwood City, CA

SR One Capital Management, LP reported $389,283,283 across 12 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-13. Its ten largest share positions make up 98.26% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-004926

Period
2025-03-31
Reported value
$389M
Holdings
12
Top 10 weight
98.26%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MLYSadded+1,111,111$17.6M
OCSnew+322,500$6.14M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0000950123-25-004926, largest first. % of portfolio is the value over $389,283,283, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,346,630 shares; 2024Q4: 2,346,630 shares; 2025Q1: 2,346,630 shares 2,346,630$154M39.54%0Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,012,903 shares; 2024Q4: 4,012,903 shares; 2025Q1: 4,012,903 shares 4,012,903$50.5M12.97%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,016,822 shares; 2024Q4: 2,016,822 shares; 2025Q1: 3,127,933 shares 3,127,933$49.7M12.76%+1,111,111Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,911,539 shares; 2024Q4: 4,911,539 shares; 2025Q1: 4,911,539 shares 4,911,539$38.8M9.97%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,048,951 shares; 2024Q4: 1,048,951 shares; 2025Q1: 1,048,951 shares 1,048,951$35.7M9.17%0Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,526,476 shares; 2024Q4: 6,526,476 shares; 2025Q1: 6,526,476 shares 6,526,476$25.2M6.47%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,959,896 shares; 2024Q4: 1,959,896 shares; 2025Q1: 1,959,896 shares 1,959,896$12M3.09%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 322,500 shares 322,500$6.14M1.58%newTimeline
NKTXNKARTA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,333,333 shares; 2024Q4: 3,333,333 shares; 2025Q1: 3,333,333 shares 3,333,333$6.13M1.58%0Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 375,330 shares; 2024Q4: 430,330 shares; 2025Q1: 430,330 shares 430,330$4.42M1.13%0Timeline
KALAKALA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 443,661 shares; 2024Q4: 598,940 shares; 2025Q1: 598,940 shares 598,940$3.43M0.88%0Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 747,750 shares; 2024Q4: 747,750 shares; 2025Q1: 747,750 shares 747,750$3.35M0.86%0Timeline

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-004926 base2025-05-13acceptance time not in the bulk data set